These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1135 related articles for article (PubMed ID: 7805002)

  • 21. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
    Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R
    J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha.
    Vaishampayan U; Abrams J; Darrah D; Jones V; Mitchell MS
    Clin Cancer Res; 2002 Dec; 8(12):3696-701. PubMed ID: 12473578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapy of malignant melanoma.
    Oratz R; Bystryn JC
    Dermatol Clin; 1991 Oct; 9(4):669-82. PubMed ID: 1718648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current management of metastatic melanoma.
    Trinh VA
    Am J Health Syst Pharm; 2008 Dec; 65(24 Suppl 9):S3-8. PubMed ID: 19052264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
    Garbe C
    Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part I: Management of stage III disease.
    Fox MC; Lao CD; Schwartz JL; Frohm ML; Bichakjian CK; Johnson TM
    J Am Acad Dermatol; 2013 Jan; 68(1):1.e1-9; quiz 10-12. PubMed ID: 23244383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance.
    Doveil GC; Fierro MT; Novelli M; Appino A; Bertero M; Quaglino P; Bernengo MG
    Dermatology; 1995; 191(3):234-9. PubMed ID: 8534942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Systemic therapy of metastatic malignant melanoma].
    Stahel RA; Martz G
    Schweiz Rundsch Med Prax; 1988 Apr; 77(17):459-62. PubMed ID: 3259710
    [No Abstract]   [Full Text] [Related]  

  • 30. Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting.
    Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R
    Melanoma Res; 2008 Apr; 18(2):152-60. PubMed ID: 18337653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
    Rosenberg SA; White DE
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):81-4. PubMed ID: 8859727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM
    J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
    Lacreusette A; Lartigue A; Nguyen JM; Barbieux I; Pandolfino MC; Paris F; Khammari A; Dréno B; Jacques Y; Blanchard F; Godard A
    J Pathol; 2008 Dec; 216(4):451-9. PubMed ID: 18798220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Finally, a successful adjuvant therapy for high-risk melanoma.
    Balch CM; Buzaid AC
    J Clin Oncol; 1996 Jan; 14(1):1-3. PubMed ID: 8558183
    [No Abstract]   [Full Text] [Related]  

  • 36. Current and planned multicenter trials for patients with primary or metastatic melanoma.
    Sondak VK; Han D; Deneve J; Kudchadkar R
    J Surg Oncol; 2011 Sep; 104(4):430-7. PubMed ID: 21858839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Melanoma and immunotherapy.
    Eggermont AM; Schadendorf D
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):547-64, ix-x. PubMed ID: 19464602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
    Mitchell MS; Abrams J; Thompson JA; Kashani-Sabet M; DeConti RC; Hwu WJ; Atkins MB; Whitman E; Ernstoff MS; Haluska FG; Jakowatz JG; Das Gupta TK; Richards JM; Samlowski WE; Costanzi JJ; Aronson FR; Deisseroth AB; Dudek AZ; Jones VE
    J Clin Oncol; 2007 May; 25(15):2078-85. PubMed ID: 17513813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Schallmach E; Kubi A; Shalmon B; Hardan I; Catane R; Segal E; Markel G; Apter S; Nun AB; Kuchuk I; Shimoni A; Nagler A; Schachter J
    J Immunother; 2009 May; 32(4):415-23. PubMed ID: 19342963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. More on cutaneous reactions to recombinant cytokine therapy.
    Le Gal FA; Paul C; Chemaly P; Dubertret L
    J Am Acad Dermatol; 1996 Oct; 35(4):650-1. PubMed ID: 8859310
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 57.